Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2007, Pages

  Mukundan, Anitha ^a   Faulkner, G E J ^b   Cohn, T ^b   Remington, G ^b  

^a Becklin Centre   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

CLINICAL PROTOCOL; CLINICAL RESEARCH; COCHRANE LIBRARY; DATA ANALYSIS; DRUG SAFETY; DRUG SUBSTITUTION; HUMAN; METABOLIC DISORDER; METHODOLOGY; OBESITY; OUTCOMES RESEARCH; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN;

EID: 44949169679     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006629     Document Type: Review

References (45)

1. ADA/APA 2004 American Diabetes Association, the American Psychiatric Association, the American Association of Clinical Endocrinologists, and the North American Association for the Study of Obesity. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care 2004;27:596-601.
2. Allison 1999 Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: A comprehensive research synthesis. American Journal of Psychiatry 1999;156:1686-89.
3. Allison 2003 Allison DB, Mackell JA, McDonnell DD. The impact of weight gain on quality of life among persons with schizophrenia. Psychiatric Services 2003;54:565-67.
4. Altman 1996 Altman DG, Bland JM. Detecing skewness from summary information. BMJ 1996;313:1200.
5. Birt 2003 Birt J. Management of weight gain associated with antipsychotics. Annals of Clinical Psychiatry 2003;15:49-58.
6. Bland 1997 Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
7. Boissel 1999 Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, Boutitie F, Nony P, Haugh M, Mignot G. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use. Therapie 1999;54(4):405-11.
8. Carpenter 1994 Carpenter WT Jr, Buchanan RW. Schizophrenia. New England Journal of Medicine 1994;330:681-90.
9. Casey 2004 Casey DE, Haupt DW, Newcomer JW, Henderson DC, Sernyak MJ, Davidson M, Lindenmayer JP, Manoukian SV, Banerji, MA, Lebovitz HE, Hennekens CH. Antipsychotic-induced weight gain and metabolic abnormalities: Implications for increased mortality in patients with schizophrenia. Journal of Clinical Psychiatry 2004;65(suppl 7):4-18.
10. Catapana 2004 Catapana L, Castle D. Obesity in schizophrenia: What can be done about it?. Australasian Psychiatry 2004;12:23-25.
11. Cohn 2004 Cohn T, Prud'homme D, Streiner D, Kameh H, Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: High prevalence of themetabolic syndrome. Canadian Journal of Psychiatry 2004;49:753-60.
12. Coodin 2001 Coodin S. Body mass index in persons with schizophrenia. Canadian Journal of Psychiatry 2001;46:549-55.
13. Daumit 2003 Daumit GL, Clark JM, Steinwachs DM, Graham CM, Lehman A, Ford DE. Prevalence and correlates of obesity in a community sample of individuals with severe and persistent mental illness. The Journal of Nervous and Mental Disease 2003;191:799-805.
14. De Nayer 2005 De Nayer A, De Hert M, Scheen A, Van Gaal L, Peuskens J on behalf of the Consensus Group. Belgian consensus on metabolic problems associated with atypical antipsychotics. International Journal of Psychiatry in Clinical Practice 2005;9:130-7.
15. Deeks 2000 Deeks J. Issues in the selection for meta-analyses of binary data. Abstracts of 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa. 2000.
16. Divine 1992 Divine GW, Brown JT, Frazer LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7:623-9.
17. DoH 2004 Department of Health. At least five a week. A report from the Chief Medical Officer. HMSO, London, 2004.
18. Donner 2002 Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
19. Faulkner 2007 Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia. Cochrane Database of Systematic Reviews 2007, Issue 1.Art. No.: CD005148. DOI:10.1002/14651858.CD005148. pub2.
20. Goff 2005 Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah NA, Daumit GL, Lamberti S, D'Agostino RB, Stroup TS, Davis S, Lieberman JA. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophrenia Research 2005;80:45-53.
21. Green 2000 Green A, Patel J, & Goisman R. Weight gain from novel antipsychotic drugs: Need for action. General Hospital Psychiatry 2000;22:224-35.
22. Gulliford 1999 Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
23. Guy 1976 Guy U. ECDEU assessment manual for psychopharmacology. Revised. Rockville: National Institute of Mental Health, 1976.
24. Henderson 2005 Henderson DC, Nguyen DD, Copeland PM, Hayden DL, Borba CP, Louie PM, Freudenreich O, Eden Evins A, Cather C, Goff DC. Clozapine, diabetesmellitus, hyperlipidemia, and cardiovascular risks and mortality: Results of a 10-year naturalistic study. Journal of Clinical Psychiatry 2005;66:1116-21.
25. Hester 2005 Hester EK, Thrower MR. Current Options in the Management of Olanzapine -Associated weight Gain. The Annals of Pharmacotherapy 2005;39(2):302-10.
26. Higgins 2003 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
27. Higgins 2005 Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. The Cochrane Library 2005, issue Issue 3.
28. Homel 2002 Homel P, Casey D, Allison DB. Changes in body mass index for individuals with and without schizophrenia. Schizophrenia Research 2002;55:277-84.
29. IDF 2006 IDF consensus worldwide definition of the metabolic syndrome. International Diabetic Federation 2006.
30. Kurzthaler 2001 Kurzthaler I, Fleischhacker WW. The clinical implications of weight gain in schizophrenia. Journal of Clinical Psychiatry 2001;62(Supple 7):32-7.
31. Le Fevre 2001 Le Fevre PD. Improving the physical health of patients with schizophrenia: Therapeutic nihilism or realism?. Scottish Medical Journal 2001;46:11-31.
32. Mackin 2005 Mackin P, Watkinson HM, Young AH. Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: A cross-sectional study. Diabetologia 2005;48:215-21.
33. Marshall 2000 Marshall M, Lockwood A, Adams C, Bradley C, Joy C, Fenton M. Unpublished rating scales - a major source of bias in randomised controlled trials of treatments for schizophrenia?. British Journal of Psychiatry 2000;176:249-52.
34. Osborn 2001 Osborn DPJ. The poor physical health of people with mental illness. Western Journal of Medicine 2001;175:329-32.
35. Reid 2003 Reid LD, Renner BT, Bengston MA, Wilcox BM, Acholonu WW. Weight Change After an Atypical Antipsychotic Switch. The Annals of Pharmacotherapy 2003;37(10):1381-86.
36. Remington 2005 Remington G, Chue P, Stip E, Kopala L, Girard T, Christensen B. The Crossover approach to switching antipsychotics: What is the evidence?. Schizophrenia Research 2005;76:267-72.
37. Saari 2005 Saari KM, Lindeman SM, Viilo KM, Isohanni MK, Jarvelin MR, Lauren LH, Savolainen MJ, Koponen HJ. A 4-fold risk of metabolic syndrome in patients with schizophrenia: The Northern Finland 1966 birth cohort study. Journal of Clinical Psychiatry 2005;66:559-63.
38. Schulz 1995 Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
39. Silverstone 1988 Silverstone T, Smith G, Goodall E. Prevalence of obesity in patients receiving depot antipsychotics. British Journal of Psychiatry 1988;153:214-17.
40. Strassnig 2003 Strassnig M, Brar JS, Ganguli R. Body mass index and quality of life in community-dwelling patients with schizophrenia. Schizophrenia Research 2003;62:73-6.
41. Susce 2005 Susce MT, Villanueva N, Diaz FJ, de Leon J. Obesity and associated complications in patients with severe mental illnesses: A cross-sectional survey. Journal of Clinical Psychiatry 2005;66:167-73.
42. Ukoumunne 1999 Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review. Health Technology Assessment 1999;3(5):iii-92. [MEDLINE: 10982317].
43. Weiden 2004 Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophrenia Research 2004;66:51-7.
44. Wikipedia 2007 Wikipedia. Europoid. http://en.wikipedia.org/wiki/ Europoid January 2007.
45. Wirshing 2004 Wirshing DA. Schizophrenia and obesity: impact of antipsychotic medications. Journal of Clinical Psychiatry 2004;65 Suppl 18:13-26.